Beit Jala Pharmaceutical Company (PEX:BJP)
Palestine · Delayed Price · Currency is JOD 3.620
+0.020 (0.56%)
At close: Jan 13, 2026
PEX:BJP Income Statement
Financials in millions JOD. Fiscal year is January - December.
Millions JOD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12.81 | 12.78 | 9.66 | 9.61 | 10.77 | 9.76 | |
Revenue Growth | 11.34% | 32.28% | 0.54% | -10.73% | 10.37% | 12.26% |
Cost of Revenue | 8.34 | 7.8 | 6.48 | 6.15 | 6.75 | 6.96 |
Gross Profit | 4.47 | 4.98 | 3.19 | 3.46 | 4.02 | 2.79 |
Selling, General & Admin | 1.82 | 1.66 | 1.26 | 1.3 | 1.66 | 1.69 |
Operating Expenses | 1.82 | 1.66 | 1.26 | 1.3 | 1.66 | 1.69 |
Operating Income | 2.65 | 3.32 | 1.92 | 2.16 | 2.35 | 1.11 |
Interest Expense | -0.05 | -0.05 | -0.11 | -0.11 | -0.12 | -0.09 |
Currency Exchange Gain (Loss) | -0.27 | -0.27 | 0.06 | -0.1 | 0.12 | 0.03 |
Other Non Operating Income (Expenses) | 0.03 | 0.01 | - | 0.01 | 0.01 | 0.01 |
Pretax Income | 2.34 | 3 | 1.87 | 1.96 | 2.36 | 1.05 |
Income Tax Expense | 0.17 | 0.27 | 0.12 | 0.12 | 0.38 | 0.18 |
Net Income | 2.17 | 2.73 | 1.76 | 1.84 | 1.98 | 0.87 |
Net Income to Common | 2.17 | 2.73 | 1.76 | 1.84 | 1.98 | 0.87 |
Net Income Growth | -14.69% | 55.69% | -4.42% | -7.26% | 127.43% | 16.87% |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 | 7 |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 7 | 7 |
Shares Change | -0.09% | - | - | - | - | - |
EPS (Basic) | 0.31 | 0.39 | 0.25 | 0.26 | 0.28 | 0.12 |
EPS (Diluted) | 0.31 | 0.39 | 0.25 | 0.26 | 0.28 | 0.12 |
EPS Growth | -14.61% | 55.69% | -4.42% | -7.26% | 127.43% | 16.87% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1.72 | 0.15 | 0.22 | 0.67 | 2.81 | 0.27 |
Free Cash Flow Per Share | -0.25 | 0.02 | 0.03 | 0.10 | 0.40 | 0.04 |
Dividend Per Share | - | - | 0.120 | 0.100 | 0.100 | 0.100 |
Dividend Growth | - | - | 20.00% | 0% | 0% | 0% |
Gross Margin | 34.91% | 38.96% | 32.99% | 36.00% | 37.31% | 28.63% |
Operating Margin | 20.71% | 25.99% | 19.91% | 22.45% | 21.87% | 11.35% |
Profit Margin | 16.96% | 21.39% | 18.17% | 19.11% | 18.40% | 8.93% |
Free Cash Flow Margin | -13.47% | 1.14% | 2.26% | 6.97% | 26.14% | 2.75% |
EBITDA | 5.74 | 6.29 | 2.6 | 3.26 | 3.31 | 2.12 |
EBITDA Margin | 44.79% | 49.24% | 26.95% | 33.90% | 30.70% | 21.69% |
D&A For EBITDA | 3.08 | 2.97 | 0.68 | 1.1 | 0.95 | 1.01 |
EBIT | 2.65 | 3.32 | 1.92 | 2.16 | 2.35 | 1.11 |
EBIT Margin | 20.71% | 25.99% | 19.91% | 22.45% | 21.87% | 11.35% |
Effective Tax Rate | 7.12% | 8.87% | 6.18% | 6.29% | 16.22% | 17.21% |
Advertising Expenses | - | 0.02 | 0.03 | 0.04 | 0.08 | 0.07 |